How to cite item

Osimertinib a new weapon in epidermal growth factor receptor-mutated non-small cell lung cancer patients

   
@article{TCR13555,
	author = {Antonio Rossi},
	title = {Osimertinib a new weapon in epidermal growth factor receptor-mutated non-small cell lung cancer patients},
	journal = {Translational Cancer Research},
	volume = {6},
	number = {Suppl 3},
	year = {2017},
	keywords = {},
	abstract = {Non-small-cell lung cancer (NSCLC) accounts for about 85% of all new lung cancer diagnoses every year worldwide (1). Unfortunately, in most cases the diagnosis is made when the disease is already in a metastatic stage with the systemic therapy being the standard-of-care. In approximatively 20% of Caucasian NSCLC patients (2), and in about 50% of Eastern Asian ones (3), an oncogene-addicted NSCLC is diagnosed, due to the presence of epidermal growth factor receptor (EGFR) activating mutations or anaplastic lymphoma kinase (ALK) and proto-oncogene tyrosine-protein kinase ROS (ROS1) rearrangements. These gene alterations identify patients who benefit from the use of correspondent inhibitors (4,5).},
	issn = {2219-6803},	url = {https://tcr.amegroups.org/article/view/13555}
}